Genomadix​

      Molecular Testing.When and Where yo Need it.

      Canada - Ontario - Ottawa
      Startup

      Genomadix has developed the Cube, the world’s first real-time PCR point of need platform for precision medicine testing and other applications.Genomadix produces molecular tests for precision medicine genotyping and environmental/water safety testing.
      Genomadix commercializes the Cube CYP2C19 Genotyping Test, the world’s fastest and easiest FDA-cleared CYP2C19 genotyping test, which can be used to support dual antiplatelet therapy decisions for stroke and cardiology patients.
      The Genomadix Cube is a point of care open platform, and is available for partnering with assay developers, clinical labs, laboratory service providers, and others.
      Genomadix’s technology for the cube includes over 3 million hours of research and development, 11 patents and 23 peer-reviewed scientific publications

      • IO ScaleUp

        IO ScaleUp

        This program is for high-growth technology firms that have reached $2 million in revenue or capital and are on track to generating $100 million or more.

        Accelerator
      Steve Edgett

      Steve Edgett

      • Chief Executive Officer (CEO)
      Jeremy bridge-Cook

      Jeremy bridge-Cook

      • Vice President, Research & Development (R&D)
      • Chief Scientific Officer (CSO)
      Sean tomalty

      Sean tomalty

      • Chief Operating Officer (COO)
      Rick Clements

      Rick Clements

      • CFO: Chief Financial Officer
      HyIvy

      HyIvy

      • Your resource for innovative care, community & confidence for your pelvic floor.
      Doctalk

      Doctalk

      • A space for physicians to collaborate with patients, organizations and each other
      MedReddie

      MedReddie

      • Transforming Healthcare Buying and Selling for Better Outcomes
      Genomadix​